DNA Revolution | Twist Bioscience leads synthetic biology with innovative DNA synthesis and storage solutions, positioning itself at the forefront of genomics and biotechnology advancements. |
Financial Resilience | Despite projected near-term losses, Twist demonstrates strong revenue growth and improving gross margins, with a target of 50% by Q4 2025. |
Storage Breakthrough | Discover how Twist's Century Archive Solution for DNA data storage could revolutionize the multi-billion dollar data storage market. |
Market Outlook | Analysts project varied price targets ranging from $45 to $55, reflecting Twist's potential in expanding synthetic biology applications across industries. |
Metrics to compare | TWST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTWSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −52.0x | −24.5x | −0.2x | |
PEG Ratio | 0.84 | −0.06 | 0.00 | |
Price/Book | 7.6x | 2.3x | 2.6x | |
Price / LTM Sales | 14.7x | 15.1x | 2.7x | |
Upside (Analyst Target) | 19.8% | 32.4% | 66.0% | |
Fair Value Upside | Unlock | −25.7% | 10.8% | Unlock |
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.